South Korea vows support for biopharmaceutical, auto sectors over US tariffs

South Korea's government announced it will provide additional support to key export industries, particularly biopharmaceutical and auto sectors, in response to potential U.S. tariffs under President Trump. The government will formulate specific support measures for biopharmaceutical companies once tariff details are available, noting that 16% of South Korea's $9.59 billion in pharmaceutical exports went to the U.S. in 2024. Seoul is also seeking tariff exemptions from Washington through ongoing trade talks, aiming to finalize a trade package by early July.

Analysis

The South Korean government has proactively pledged additional support measures for its key export industries, specifically targeting the biopharmaceutical and automotive sectors, in anticipation of potential U.S. tariffs. This governmental intervention is a direct response to U.S. President Donald Trump's trade policies, including an executive order aimed at bolstering domestic pharmaceutical manufacturing and probes into pharmaceutical imports which could lead to tariffs. South Korea's pharmaceutical exports reached $9.59 billion in 2024, with a significant 16% share destined for the United States, its largest market, underscoring the potential impact of such tariffs. While overall South Korean exports showed unexpected resilience recently, largely driven by semiconductor demand, there are emergent signs that global trade tensions, particularly U.S. tariffs, are beginning to negatively affect its crucial auto sector. Seoul is actively engaged in technical discussions with Washington, seeking exemptions from all tariffs and aiming to finalize a comprehensive trade package by early July, following earlier support packages for industries like chipmaking and steel manufacturing. The situation reflects a cautious outlook, with the government preparing to act swiftly once details of the U.S. tariffs on the biopharmaceutical sector are clarified.

Key Decisions for Investors

• Investors should closely monitor the outcome of the ongoing US-South Korea trade negotiations, as any exemptions secured or the specifics of the trade package due by early July will be critical determinants for the affected sectors' performance.
• Holders of South Korean biopharmaceutical and automotive equities need to assess the potential earnings impact from new US tariffs against the cushioning effect of the pledged government support measures.
• Given the current uncertainty surrounding the scope and implementation of US tariffs, a cautious stance is advisable regarding new investments in these export-dependent South Korean sectors until greater clarity emerges on both the tariffs and the efficacy of governmental countermeasures.